Følg
sibylle loibl
sibylle loibl
Professor for medicine
Bekræftet mail på gbg.de
Titel
Citeret af
Citeret af
År
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ...
Annals of oncology 24 (9), 2206-2223, 2013
36452013
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, ...
The Lancet 384 (9938), 164-172, 2014
33792014
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
G Von Minckwitz, M Untch, JU Blohmer, SD Costa, H Eidtmann, ...
J Clin oncol 30 (15), 1796-1804, 2012
23792012
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ...
Annals of oncology 26 (2), 259-271, 2015
20582015
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer
C Denkert, S Loibl, A Noske, M Roller, BM Muller, M Komor, J Budczies, ...
J Clin Oncol 28 (1), 105-113, 2010
16502010
Palbociclib in hormone-receptor–positive advanced breast cancer
NC Turner, J Ro, F André, S Loi, S Verma, H Iwata, N Harbeck, S Loibl, ...
New England Journal of Medicine 373 (3), 209-219, 2015
14492015
Trastuzumab emtansine for residual invasive HER2-positive breast cancer
G Von Minckwitz, CS Huang, MS Mano, S Loibl, EP Mamounas, M Untch, ...
New England Journal of Medicine 380 (7), 617-628, 2019
14312019
Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
F André, E Ciruelos, G Rubovszky, M Campone, S Loibl, HS Rugo, ...
New England Journal of Medicine 380 (20), 1929-1940, 2019
14022019
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, ...
Annals of oncology 25 (8), 1544-1550, 2014
11552014
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
C Denkert, G von Minckwitz, S Darb-Esfahani, B Lederer, BI Heppner, ...
The lancet oncology 19 (1), 40-50, 2018
11282018
Association analysis identifies 65 new breast cancer risk loci
K Michailidou, S Lindström, J Dennis, J Beesley, S Hui, S Kar, A Lemaçon, ...
Nature 551 (7678), 92-94, 2017
10162017
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ...
Annals of Oncology 28 (8), 1700-1712, 2017
10052017
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
G Von Minckwitz, A Schneeweiss, S Loibl, C Salat, C Denkert, M Rezai, ...
The lancet oncology 15 (7), 747-756, 2014
9382014
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative …
C Denkert, G Von Minckwitz, JC Brase, BV Sinn, S Gade, R Kronenwett, ...
J Clin oncol 33 (9), 983-991, 2015
9332015
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
M Kaufmann, GN Hortobagyi, A Goldhirsch, S Scholl, A Makris, ...
Journal of Clinical Oncology 24 (12), 1940-1949, 2006
8722006
Trastuzumab beyond progression in human epidermal growth factor receptor 2–positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study
G von Minckwitz, A du Bois, M Schmidt, N Maass, T Cufer, FE de Jongh, ...
Journal of Clinical Oncology 27 (12), 1999-2006, 2009
8052009
Overall survival with palbociclib and fulvestrant in advanced breast cancer
NC Turner, DJ Slamon, J Ro, I Bondarenko, SA Im, N Masuda, M Colleoni, ...
New England journal of medicine 379 (20), 1926-1936, 2018
7472018
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ...
New England Journal of Medicine 382 (7), 597-609, 2020
7082020
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
NU Lin, V Diéras, D Paul, D Lossignol, C Christodoulou, HJ Stemmler, ...
Clinical cancer research 15 (4), 1452-1459, 2009
6862009
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
B Asselain, W Barlow, J Bartlett, J Bergh, E Bergsten-Nordström, J Bliss, ...
The Lancet Oncology 19 (1), 27-39, 2018
6622018
Systemet kan ikke foretage handlingen nu. Prøv igen senere.
Artikler 1–20